CIBC Private Wealth Group
TEVA icon

CIBC Private Wealth Group’s Teva Pharmaceuticals TEVA Stock Holding History

CIBC Private Wealth Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$155K Buy
4,953
+933
+23% +$23K ﹤0.01% 1321
2025
Q3 		$81.2K Buy
4,020
+540
+16% +$9.48K ﹤0.01% 1590
2025
Q2 		$58.3K Hold
3,480
– – ﹤0.01% 1602
2025
Q1 		$47.3K Sell
3,480
-708
-17% -$12.6K ﹤0.01% 1647
2024
Q4 		$90K Sell
4,188
-461
-10% -$8.39K ﹤0.01% 1460
2024
Q3 		$83.8K Buy
4,649
+38
+0.8% +$665 ﹤0.01% 1566
2024
Q2 		$75.4K Buy
4,611
+3,903
+551% +$60.1K ﹤0.01% 1505
2024
Q1 		$9.85K Buy
+708
New +$8.92K ﹤0.01% 2283
2019
Q3 		– Sell
-13,840
Closed -$128K – 941
2019
Q2 		$128K Sell
13,840
-600
-4% -$7.24K ﹤0.01% 897
2019
Q1 		$226K Sell
14,440
-73,100
-84% -$1.29M ﹤0.01% 876
2018
Q4 		$1.35M Buy
87,540
+1,000
+1% +$20.5K 0.01% 513
2018
Q3 		$1.86M Buy
86,540
+68,600
+382% +$1.59M 0.01% 522
2018
Q2 		$436K Buy
17,940
+1,480
+9% +$30.2K ﹤0.01% 801
2018
Q1 		$281K Buy
16,460
+1,959
+14% +$38.2K ﹤0.01% 875
2017
Q4 		$275K Buy
14,501
+1,200
+9% +$18.1K ﹤0.01% 879
2017
Q3 		$234K Buy
13,301
+1,607
+14% +$36.2K ﹤0.01% 878
2017
Q2 		$388K Sell
11,694
-1,538
-12% -$47.6K ﹤0.01% 559
2017
Q1 		$424K Sell
13,232
-7,051
-35% -$241K ﹤0.01% 530
2016
Q4 		$735K Sell
20,283
-23,750
-54% -$948K ﹤0.01% 481
2016
Q3 		$2.03M Sell
44,033
-786
-2% -$41K 0.01% 362
2016
Q2 		$2.25M Sell
44,819
-300
-0.7% -$16K 0.02% 350
2016
Q1 		$2.41M Sell
45,119
-1,960
-4% -$115K 0.02% 332
2015
Q4 		$3.09M Buy
47,079
+1,103
+2% +$68.2K 0.02% 311
2015
Q3 		$2.6M Buy
45,976
+3,000
+7% +$195K 0.02% 328
2015
Q2 		$2.54M Buy
42,976
+4,866
+13% +$300K 0.02% 351
2015
Q1 		$2.38M Buy
38,110
+9,993
+36% +$581K 0.02% 357
2014
Q4 		$1.62M Buy
28,117
+465
+2% +$25.9K 0.01% 401
2014
Q3 		$1.49M Sell
27,652
-10,285
-27% -$545K 0.01% 398
2014
Q2 		$1.99M Sell
37,937
-440
-1% -$22.5K 0.02% 366
2014
Q1 		$2.05M Buy
+38,377
New +$1.77M 0.02% 362

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

CIBC Private Wealth Group's TEVA Position: Q4 2025 in Review

CIBC Private Wealth Group increased its Teva Pharmaceuticals (TEVA) stake by 23% in Q4 2025, buying an estimated $23K and bringing the position to 4,953 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

CIBC Private Wealth Group first reported a position in TEVA in Q1 2014 and has held it in 30 quarters since. The position peaked at $3.09M in Q4 2015. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • CIBC Private Wealth Group held 4,953 shares of Teva Pharmaceuticals worth $155K as of Q4 2025.
  • CIBC Private Wealth Group bought 933 Teva Pharmaceuticals shares in Q4 2025, an estimated $23K.
  • Teva Pharmaceuticals made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #1321 holding.
  • CIBC Private Wealth Group first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 30 quarters since.
  • CIBC Private Wealth Group's Teva Pharmaceuticals position peaked at $3.09M in Q4 2015.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.